202 related articles for article (PubMed ID: 31102402)
1. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.
Jaspers NEM; Blaha MJ; Matsushita K; van der Schouw YT; Wareham NJ; Khaw KT; Geisel MH; Lehmann N; Erbel R; Jöckel KH; van der Graaf Y; Verschuren WMM; Boer JMA; Nambi V; Visseren FLJ; Dorresteijn JAN
Eur Heart J; 2020 Mar; 41(11):1190-1199. PubMed ID: 31102402
[TBL] [Abstract][Full Text] [Related]
2. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
[TBL] [Abstract][Full Text] [Related]
3. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2.
Hageman SHJ; Petitjaen C; Pennells L; Kaptoge S; Pajouheshnia R; Tillmann T; Blaha MJ; McClelland RL; Matsushita K; Nambi V; Klungel OH; Souverein PC; van der Schouw YT; Verschuren WMM; Lehmann N; Erbel R; Jöckel KH; Di Angelantonio E; Visseren FLJ; Dorresteijn JAN
Eur J Prev Cardiol; 2023 Oct; 30(15):1705-1714. PubMed ID: 37264679
[TBL] [Abstract][Full Text] [Related]
4. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.
LIFE-CVD2 Working Group
Eur J Prev Cardiol; 2024 May; ():. PubMed ID: 38752762
[TBL] [Abstract][Full Text] [Related]
5. Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
Hageman SHJ; Dorresteijn JAN; Bots ML; Asselbergs FW; Westerink J; van der Meulen MP; Mosterd A; Visseren FLJ; ; Asselbergs FW; Nathoe HM; de Borst GJ; Bots ML; Geerlings MI; Emmelot MH; de Jong PA; Leiner T; Lely AT; van der Kaaij NP; Kappelle LJ; Ruigrok YM; Verhaar MC; Visseren FLJ; Westerink J
Eur J Prev Cardiol; 2022 Mar; 29(4):635-644. PubMed ID: 34009323
[TBL] [Abstract][Full Text] [Related]
6. A cardiovascular risk prediction model for older people: Development and validation in a primary care population.
van Bussel EF; Richard E; Busschers WB; Steyerberg EW; van Gool WA; Moll van Charante EP; Hoevenaar-Blom MP
J Clin Hypertens (Greenwich); 2019 Aug; 21(8):1145-1152. PubMed ID: 31294917
[TBL] [Abstract][Full Text] [Related]
7. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
de Vries TI; Eikelboom JW; Bosch J; Westerink J; Dorresteijn JAN; Alings M; Dyal L; Berkowitz SD; van der Graaf Y; Fox KAA; Visseren FLJ
Eur Heart J; 2019 Dec; 40(46):3771-3778a. PubMed ID: 31504399
[TBL] [Abstract][Full Text] [Related]
8. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.
Ferket BS; van Kempen BJ; Heeringa J; Spronk S; Fleischmann KE; Nijhuis RL; Hofman A; Steyerberg EW; Hunink MG
PLoS Med; 2012; 9(12):e1001361. PubMed ID: 23300388
[TBL] [Abstract][Full Text] [Related]
9. Prediction of individualized lifetime benefit from cardiovascular risk-reducing interventions in apparently healthy people.
Echouffo-Tcheugui JB; Kengne AP
Eur Heart J; 2020 Mar; 41(11):1200-1202. PubMed ID: 31369081
[No Abstract] [Full Text] [Related]
10. Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
Helmink MAG; Hageman SHJ; Eliasson B; Sattar N; Visseren FLJ; Dorresteijn JAN; Harris K; Peters SAE; Woodward M; Szentkúti P; Højlund K; Henriksen JE; Sørensen HT; Serné EH; van Sloten TT; Thomsen RW; Westerink J
Diabetes Obes Metab; 2024 Jun; 26(6):2229-2238. PubMed ID: 38456579
[TBL] [Abstract][Full Text] [Related]
11. The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.
Guthrie B; Rogers G; Livingstone S; Morales DR; Donnan P; Davis S; Youn JH; Hainsworth R; Thompson A; Payne K
Health Soc Care Deliv Res; 2024 Feb; 12(4):1-275. PubMed ID: 38420962
[TBL] [Abstract][Full Text] [Related]
12. A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality.
Støvring H; Harmsen CG; Wisløff T; Jarbøl DE; Nexøe J; Nielsen JB; Kristiansen IS
Eur J Prev Cardiol; 2013 Oct; 20(5):827-36. PubMed ID: 22498473
[TBL] [Abstract][Full Text] [Related]
13. Sex-specific lifetime risk of cardiovascular events: the European Prospective Investigation into Cancer-Norfolk prospective population cohort study.
Pana TA; Mamas MA; Wareham NJ; Khaw KT; Dawson DK; Myint PK
Eur J Prev Cardiol; 2024 Jan; 31(2):230-241. PubMed ID: 38031203
[TBL] [Abstract][Full Text] [Related]
14. Global cardiovascular mortality risk in the adult Polish population: prospective assessment of the cohorts studied in multicentre national WOBASZ and WOBASZ Senior studies.
Piotrowski W; Waśkiewicz A; Cicha-Mikołajczyk A
Kardiol Pol; 2016; 74(3):262-73. PubMed ID: 26365939
[TBL] [Abstract][Full Text] [Related]
15. External validation of the QLifetime cardiovascular risk prediction tool: population cohort study.
Livingstone S; Morales DR; Fleuriot J; Donnan PT; Guthrie B
BMC Cardiovasc Disord; 2023 Apr; 23(1):194. PubMed ID: 37061672
[TBL] [Abstract][Full Text] [Related]
16. The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation.
Jaspers NEM; Ridker PM; Dorresteijn JAN; Visseren FLJ
Curr Opin Lipidol; 2018 Dec; 29(6):436-444. PubMed ID: 30234556
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model.
Helmink MAG; Peters SAE; Westerink J; Harris K; Tillmann T; Woodward M; van Sloten TT; van der Meer MG; Teraa M; Dorresteijn JAN; Ruigrok YM; Visseren FLJ; Hageman SHJ;
Eur J Prev Cardiol; 2024 Apr; ():. PubMed ID: 38584392
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.
Rubinstein A; Colantonio L; Bardach A; Caporale J; Martí SG; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
BMC Public Health; 2010 Oct; 10():627. PubMed ID: 20961456
[TBL] [Abstract][Full Text] [Related]
19. Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: The LIFE-HF model.
Burger PM; Savarese G; Tromp J; Adamson C; Jhund PS; Benson L; Hage C; Tay WT; Solomon SD; Packer M; Rossello X; McEvoy JW; De Bacquer D; Timmis A; Vardas P; Graham IM; Di Angelantonio E; Visseren FLJ; McMurray JJV; Lam CSP; Lund LH; Koudstaal S; Dorresteijn JAN; Mosterd A;
Eur J Heart Fail; 2023 Nov; 25(11):1962-1975. PubMed ID: 37691140
[TBL] [Abstract][Full Text] [Related]
20. Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.
Jaspers NEM; Visseren FLJ; Numans ME; Smulders YM; van Loenen Martinet FA; van der Graaf Y; Dorresteijn JAN
BMJ Open; 2018 May; 8(5):e021309. PubMed ID: 29804065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
